Neha Krishnamohan - Apr 3, 2024 Form 4 Insider Report for Kinnate Biopharma Inc. (KNTE)

Role
CHIEF FINANCIAL OFFICER
Signature
/s/ James P. Reilly, Attorney-in-Fact
Stock symbol
KNTE
Transactions as of
Apr 3, 2024
Transactions value $
$0
Form type
4
Date filed
4/5/2024, 04:55 PM
Previous filing
Mar 5, 2024
Next filing
Jun 18, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KNTE Common Stock Disposed to Issuer -64.1K -100% 0 Apr 3, 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KNTE Stock Option (right to buy) Disposed to Issuer -270K -100% 0 Apr 3, 2024 Common Stock 270K $23.26 Direct F3
transaction KNTE Stock Option (right to buy) Disposed to Issuer -185K -100% 0 Apr 3, 2024 Common Stock 185K $10.03 Direct F3
transaction KNTE Stock Option (right to buy) Disposed to Issuer -215K -100% 0 Apr 3, 2024 Common Stock 215K $6.78 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Neha Krishnamohan is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Includes 42,188 shares represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of Common Stock of the Issuer.
F2 Disposed of pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for (i) $2.5879 in cash per share (the "Cash Amount"), plus (ii) one non-transferable contingent value right ("CVR") per share. Each RSU will receive the Cash Amount (without interest and less any applicable tax withholdings), plus one CVR.
F3 This option was cancelled pursuant to the Merger Agreement in exchange for one CVR for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount.